Monthly Archives: June 2017
CAR T-Cell Therapy HCP Guide – Overview: Side Effects from CAR T-Cell Therapy
CAR T-cell therapy is a potent investigational treatment used in patients with high tumor burden. A positive response to CAR T-cell therapy leads to...
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced...
December 1, 2016 (Blood)
"Chimeric antigen receptors (CARs) are fusion proteins that combine antigen-recognition domains and T-cell signaling domains."
T cells harvested from patients' blood...
CAR T-Cell Therapy Can Now Target Solid Tumors: Mouse Study
June 21, 2016 (Medical News Today)
In Phase 2 trials, chimeric antigen receptors (CARs), genetically engineered protein constructs, rewire T-cells in a patient’s own immune...
StatPearls Question of the Week – #6
To date in clinical trials, chimeric antigen receptor T (CAR-T) cell therapy has been used to treat which type of cancer?
A. Sezary syndrome
B....
CAR T-Cell Therapy HCP Guide – Solid Tumor Research: Progress to Be Made
While CAR T-cell therapy in hematologic cancers is impressive, the fact remains that most deadly cancers are solid tumors like lung, breast, or colon...
CAR T-Cell Therapy HCP Guide – Pivotal Trial: Aggressive B-Cell Non-Hodgkin Lymphoma
Aggressive B Cell Non-Hodgkin Lymphomas
About 90% of lymphoma cases start in the B cells. The C19 tumor target that is sought by the...
CAR T-Cell Therapy HCP Guide – Cancer Targets
Gene Therapy to the Rescue
The first investigational oncology gene therapy known as a chimeric antigen receptor (CAR) T-cell therapy is rapidly moving...
Kite’s CAR T-Cell Therapy Success
March 1, 2017 (The Scientist)
In the 6-month follow-up for a Phase 2 trial focused on 101 advanced non-Hodgkin lymphoma patients who underwent chimeric...
14 scientific definitions for a deeper understanding of CAR-T therapy
Many researchers, oncologists, and pharmaceutical companies hail CAR-T therapy as a “cure for cancer.” But what exactly is this evolving technology? How is it...
VIDEO: Interview with Arie Belldegrun, Kite Pharma CEO on pricing
October 17, 2016 (CNBC)
Arie Belldegrun, Kite Pharma CEO talks to CNBC's Meg Tirrell about developing cancer immunotherapy drugs with T-cells. Also Belldegrun address the...
